A Study of Evacetrapib and Rifampin in Healthy Participants

Completed · Phase 1

Conditions studied: Healthy Volunteers

In brief

The main purpose of this study is to determine how much evacetrapib gets into the blood stream and how long it takes the body to get rid of it when given with rifampin. The safety and tolerability of the two drugs, given together, will also be evaluated. The study will also look at blood cholesterol levels and levels of a hormone called cortisol before and after taking rifampin. Information about any side effects that may occur will also be collected. For each participant, this study will include 2 periods in fixed order. The study will last approximately 29 days.

Key facts

Study ID

NCT01908582

Run by

Eli Lilly and Company

People needed

26

Starts

2013-07-01

Expected to finish

2013-09-01

Last updated by the study team

2018-10-03

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Overtly healthy males and females (of non child-bearing potential)
• Have a body mass index of 18 to 32 kilograms per square meter (kg/m\^2), inclusive, at screening

You may not qualify if…

• Have known allergies to evacetrapib, rifampin, related compounds or any components of either formulation, or history of significant allergic disease as determined by the investigator

Where it is running

• For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.